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Potentiating the Activity of Nisin
against Escherichia coli
Liang Zhou, Auke J. van Heel, Manuel Montalban-Lopez and Oscar P. Kuipers *
Department of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen,
Groningen, Netherlands
Lantibiotics are antimicrobial (methyl)lanthionine-containing peptides produced by
various Gram-positive bacteria. The model lantibiotic, nisin, binds lipid II in the cell
membrane. Additionally, after binding it can insert into the membrane creating a pore.
Nisin can efficiently inhibit the growth of Gram-positive bacteria and resistance is rarely
observed. However, the activity of lantibiotics is at least 100-fold lower against certain
Gram-negative bacteria. This is caused by the fact that Gram-negative bacteria have an
outer membrane that hinders the peptides to reach lipid II, which is located in the inner
membrane. Improving the activity of lantibiotics against Gram-negative bacteria could
be achieved if the outer membrane traversing efficiency is increased. Here, several anti-
Gram-negative peptides (e.g., apidaecin 1b, oncocin), or parts thereof, were fused to the
C-terminus of either a truncated version of nisin containing the first three/five rings or full
length nisin. The activities of these fusion peptides were tested against Gram-negative
pathogens. Our results showed that when an eight amino acids (PRPPHPRL) tail from
apidaecin 1b was attached to nisin, the activity of nisin against Escherichia coli CECT101
was increasedmore than two times. This research presents a new and promising method
to increase the anti-Gram-negative activity of lantibiotics.
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INTRODUCTION
Lantibiotics are ribosomally synthesized and post-translationally modified peptides. After
modification, they consist of one or more (methyl)lanthionine rings, dehydroalanines, or
dehydrobutyrines. Additionally, some lantibiotics display additional modifications (Willey and van
der Donk, 2007). Most lantibiotics inhibit the growth of Gram-positive bacteria using lipid II as
a target molecule (Bauer and Dicks, 2005). Lipid II plays an essential role in cell-wall synthesis.
Diverse lantibiotics bind to the pyrophosphate group in lipid II, and subsequently form pores
in the membrane, which is fatal for the bacteria (Breukink et al., 1999; Hasper et al., 2006).
Specific resistance to lantibiotics is therefore rarely found (Breukink and de Kruijff, 2006; Draper
et al., 2015). However, Gram-negative bacteria have an outer membrane, which is composed of
a phospholipid layer (inside) and an outside layer of lipopolysaccharide (LPS) which contains
lipid A and polysaccharide chains (Erridge et al., 2002). The LPS is highly negative-charged and
the core oligosaccharide region is ordered by divalent cations (mainly Ca2+ and Mg2+) (Clifton
et al., 2015), which can hamper lantibiotics from reaching lipid II in the inner membrane. Thus,
enhancing the activity of lantibiotics against Gram-negative pathogens first requires improving the
outer membrane penetration capability.
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Nisin (Figure 1) produced by Lactococcus lactis is the first
identified lantibiotic (Lubelski et al., 2008). The structural gene
of nisin encodes a 57 amino acids prepeptide. The first 23 amino
acids form the leader part and the last 34 residues constitute
the core peptide. The leader peptide guides the core peptide
through the modification and transport system, and keeps nisin
inactive (Plat et al., 2013). Firstly, NisB dehydrates the serines and
threonines to form dehydroalanines (Dha) or dehydrobutyrines
(Dhb) (Ortega et al., 2015). Then NisC couples the cysteine to
the Dha or Dhb by a sulfhydryl addition reaction (Kuipers et al.,
1993; Koponen et al., 2002). The modified peptide is transported
to the outside of the cell by NisT (Kuipers et al., 2004). NisP is
a protease specifically cutting off the leader peptide liberating
active nisin (van der Meer et al., 1993). After modification,
the peptide contains five (methyl)lanthionine rings, two Dha
residues, and one Dhb. NisB and NisC have a relaxed substrate
specificity, and when the core peptide is replaced by other
sequences, the modifications can still be performed in most cases
(Kluskens et al., 2005; Rink et al., 2007a; Majchrzykiewicz et al.,
2010).
Nisin can efficiently inhibit the growth of Gram-positive
bacteria, with a minimal inhibitory concentration in the
nanomolar range. The rings A and B of nisin can bind to the
pyrophosphate of lipid II on the membrane of Gram-positive
bacteria by forming a pyrophosphate cage (Hsu et al., 2004) and
consequently inhibit cell wall synthesis. The N-terminal part is
essential for the activity of nisin, and if the C-terminal part is
deleted, moderate activity is still observed (Rink et al., 2007b).
After binding, the C-terminal part of nisin can translocate across
the membrane and form pores by assembling a pore complex in
a stoichiometry of 8 nisin and 4 lipid II molecules (Breukink and
de Kruijff, 2006).
Nisin displays much lower activity against most Gram-
negative bacteria, because the outer membrane can prevent the
peptide to reach the periplasm and to exert activity binding
lipid II in the inner membrane. When the outer membrane
is destabilized using ethylenediaminetetraacetic acid (EDTA) or
pyrophosphate, nisin can inhibit the Gram-negative bacteria
more efficiently (Boziaris and Adams, 1999; Helander and
Mattila-Sandholm, 2000). This indicates that passing the outer
membrane is crucial for the activity of nisin against Gram-
negative bacteria.
Notably, there are some antimicrobial peptides (AMPs) which
can efficiently inhibit the growth of Gram-negative bacteria,
such as apidaecin 1b, oncocin, or EC5 (Table 1). These peptides
are normally positively charged, some are proline-rich and they
all can efficiently traverse the outer membrane. In this paper
we aim to design and produce hybrid molecules that combine
the lipid II binding capacity of nisin with the ability of these
eukaryotic peptides to cross the outer membrane of Gram-
negative bacteria. Thus, the anti-Gram negative peptides or the
membrane-translocating part of them were attached to nisin
or to the N-terminal part of nisin, and the activities of the
fusions against Gram-negative bacteria were tested. One fusion
was found to have higher activity than nisin, which indicates the
potential of this approach. This is the first attempt to potentiate
the activity of nisin against Gram-negative microorganisms
by adding a tail that could facilitate traversing the outer
membrane.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
The bacterial strains used in this study are listed in Table 2. L.
lactis strains were cultured inM17 broth supplemented with 0.5%
(w/v) glucose (GM17) for genetic manipulation or in minimal
expression medium (MEM) for protein expression at 30◦C (Rink
et al., 2005). E. coli CECT101 was grown in Luria-Bertani broth
aerated by shaking (200 rpm) at 37◦C.
Molecular Cloning
A 6 his-tag was added to the leader part of nisin by PCR based
on the plasmid pNZnisA as described previously (Zhou et al.,
2015). Standard molecular cloning was performed according to
Sambrook and Russell (2001). The tails were added to nisin by
designing primers containing the sequences of the tail and a
selected part of nisin with SacI and HindIII at either end. The
primers were annealed according to the protocol on the website
of Sigma-Aldrich (1Protocol for Annealing Oligonucleotides).
The annealed double strand DNAs were ligated to the pNZnisA
leader6H vector cut by SacI and HindIII. Competent cells were
prepared and transformed as described previously (Holo and
Nes, 1995).
Protein Expression, TCA Precipitation, and
Tricine SDS-PAGE
The expression of the peptides was conducted using L. lactis
NZ9000 or L. lactis PA1001 containing the plasmids pIL3EryBTC
and pNZnisA leader6H harboring the nisin and anti-Gram
negative tail fusion. The culture and expression methods were
the same as previously described (Zhou et al., 2015). Cells
were cultured at 30◦C first in GM17 medium with 4µg/ml
chloramphenicol and 4µg/ml erythromycin until OD (600 nm)
reached 0.7, then centrifuged and resuspended in the same
amount of MEM medium with 0.5% (w/v) glucose, 3µg/ml
chloramphenicol, 3µg/ml erythromycin, and 2 nM nisin to
induce the expression of the peptides. After 3 h induction, the
supernatant was harvested. The supernatant of a small volume
of fermentation (<10ml) was concentrated by trichloroacetic
acid (TCA) precipitation (Sambrook and Russell, 2001) and
the concentrated peptides were loaded on a 16% Tricine SDS-
PAGE gel (Schägger, 2006). NisP was expressed to cleave off the
leader part of the peptides. The strain NZ9000 (pNZnisP8H) was
cultured and harvested in the same way as above, but here only
chloramphenicol was added.
Purification, Characterization, and
Quantification
For large scale purification, 2 L supernatant containing the
mature prepeptide and 100ml supernatant containing NisP
1Protocol for Annealing Oligonucleotides Sigma-Aldrich. Available online
at: http://www.sigmaaldrich.com/technical-documents/protocols/biology/
annealing-oligos.html (Accessed April 8, 2015).
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FIGURE 1 | Structure of prenisin with his-tag. The six histidine residues are labeled in blue. Dha, dehydroalanine; Dhb, dehydrobutyrine; Ala-S-Ala, lanthionine;
Abu-S-Ala, β-methyllanthionine. The rings ABCDE and the hinge region (Asn- Met-Lys) are marked; the positions of the tails are indicated. The molecular weight is
6640.7Da.
TABLE 1 | List of selected peptides with anti-Gram-negative bacteria activity.
Name Sequencea MIC(µM) References
Apidaecin 1b GNNRPVYIPQPRPPHPRL 0.5b Berthold et al., 2013
Api 88 Gu-ONNRPVYIPRPRPPHPRL-NH2 0.2
b Czihal et al., 2012
Oncocin VDKPPYLPRPRPPRRIYNR-NH2 1.7
b Knappe et al., 2010
Drosocin GKPRPYSPRPTSHPRPIRV 25c Bikker et al., 2006
EC5 RLLFRKIRRLKR 4.8d Sainath Rao et al., 2013
Bac8c RIWVIWRR-NH2 1.7
e Hilpert et al., 2005
R-BP100 KKLFKKILKYL-NH2 0.9 ± 0.4
f Torcato et al., 2013
RW-BP100 RRLFRRILRWL-NH2 0.5 ± 0.2
f Torcato et al., 2013
ADP2 GIGKHVGKALKGLKGLLKGLGEC-NH2 1
f Iliæ et al., 2013
8Rg RRRRRRRR ND Wender et al., 2000
aGu denotes N,N,N’,N’-tetramethylguanidine, and O denotes L-ornithine.The indicator strains used for minimum inhibitory concentration (MIC) tests were bE. coli BL21 AI; cE. coli
O157:H7; dE. coli ATCC 700928; eE. coli UB1005; fE. coli ATCC 25922. gOnly has membrane penetrating activity. ND, not determined.
were filtered (0.2µm membrane, Millipore), mixed together
and incubated at 30◦C for 1 h to cut off the leader peptide.
After incubation, the active peptides were first purified by
cation-ion exchange chromatography (van Heel et al., 2013).
Then, the eluate was loaded on a C18 (Spherical C18, Sigma-
Aldrich) column. The peptides were eluted with 30–40% buffer
B (Buffer A, miliQ with 0.1% trifluoroacetic acid (TFA); Buffer B,
isopropanol: acetonitrile (2:1) with 0.1% TFA). The elutions from
the C18 column were freeze dried. The freeze dried peptides were
further purified by HPLC (Agilent 1260 Infinity LC) equipped
with a semi-preparative C12 column (Phenomenex 250×10mm,
4µm, Proteo 90Å) as described previously (Zhou et al., 2015).
The fractions were collected, tested for activity against L. lactis
and analyzed by MALDI-TOF as described previously (van Heel
et al., 2013). The active, fully dehydrated, and pure fractions were
freeze dried and quantified with HPLC as described previously
(Zhou et al., 2015).
Determination of the Minimum Inhibitory
Concentration (MIC)
The indicator strains were first cultured until OD (600 nm)
reached 0.5. When testing the MIC value, the culture was diluted
1000 times with the appropriate medium. All the tests were
performed with a temperature controlled plate reader (Tecan
infinite F200, Tecan Group AG) in a 96-well plate (Greiner Bio-
one). The peptides were first diluted in gradient withmedium and
thenmixed with diluted indicator strains. The final concentration
of the peptides ranged from 0.00625 to 0.8µM against L. lactis
MG1363 and from 0.25 to 32µM against E. coli CECT101 in
100µl volume. The plate was incubated at 30◦C or 37◦C for
18 h depending on the indicator strain being L. lactis or E. coli,
respectively. OD (600 nm) was checked every 30min. For E. coli,
2min of shaking was performed before every check.When testing
the activity of nisin against E. coli in the presence of EDTA, an
EDTA solution was prepared and added to a final concentration
of 50, 110, or 250µM. The minimal concentration of peptide
causing no observed growth of indicator strains was considered
as the MIC value.
RESULTS
The Anti-Gram Negative Tails are Attached
to Different Parts of Nisin
To increase the outer membrane penetration capability of nisin,
10 different anti-Gram-negative peptides were combined with
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TABLE 2 | Strains and plasmids used in this study.
Strains or plasmids Characteristics References
STRAINS
Lactococcus lactis NZ9000 nisRK Kuipers et al., 1997
L. lactis PA1001 Derivative of NZ9000, with acmA and htrA deleted Bosma et al., 2006
PLASMIDS
pIL3EryBTC nisBTC, encoding nisin modification machinery, EryRa van Heel et al., 2013
pNZ8048 Nisin inducible promoter in shuttle vector de Ruyter et al., 1996
pNZnisA nisA, encoding nisin, CmRb, inserted in pNZ8048 van Heel et al., 2013
pNZnisA leader6H nisA, encoding nisin, with 6 histidine residues inserted
behind the first methionine
This study
pNZnisA GNT16 nisA, encoding nisin, with 6 histidine residues inserted
behind the first methionine and tail PRPPHPRL fused to
the C-terminus
This study
pNZnisA GNTs nisA, encoding nisin or part of nisin, with 6 histidine
residues inserted behind the first methionine and tails
listed in Table 3
This study
pNZnisP8H nisP, encoding a NisP mutant, with 8 histidines, CmRb Unpublished data
INDICATOR STRAINS
L. lactis MG1363 Nisin sensitive indicator Gasson, 1983
Escherichia coli CECT101 Gram-negative indicator CECT
aEryR, erythromycin resistance. bCmR, chloramphenicol resistance.
nisin in four different ways (Figure 1,Table 3). More specifically,
nisin binds to the lipid II molecule with its first two rings, a
process that consequently inhibits the synthesis of the cell wall.
Moreover, a mutant of nisin where the amino acids 23–34 were
deleted (i.e., rings DE and the C-terminal linear part of nisin)
still retains a modest antimicrobial activity (Rink et al., 2007b).
We hypothesized that by combining the ABC rings of nisin and
an anti-Gram-negative peptide tail, the fusion could gain the
potential to traverse the outer-membrane, while maintaining the
lipid II binding activity, thereby inhibiting growth. Based on this
idea, 13 different peptides were designed (Table 3 Group 1). In
the cases of apidaecin 1b and oncocin, different regions of the
peptides were linked to the first three rings of nisin. Additionally,
the PRPPHPRL tail of apidaecin 1b was added either alone
(GNT16-3rings) or as a duplicated motif (GNT5).
The full length nisin can additionally form pores in the
cytoplasmic membrane after binding to lipid II, which increases
its potency as compared to lipid II sequestering by the first three
rings (Breukink and de Kruijff, 2006). Therefore, in this research
the anti-Gram negative tails were also fused behind full length
nisin (Table 3 Group 2). In those cases where the anti-Gram-
negative tail was starting with a positively charged amino acid,
Lys34 of nisin was deleted (i.e., GNT10 and GNT12).
As some of the Group 2 peptides (e.g., GNT15) tend to be
truncated behind Val32 (data not shown), part of the C-terminal
sequence of nisin was deleted in some of the variants (Table 3
Group 3). Following a similar reasoning, the C-terminus of nisin
behind ring E was deleted and instead a Ser-Gly linker was added
as a flexible linker in front of the tail (Table 3 Group 4). An
exception in Group 4 is GNT3, because in this case the anti-
Gram-negative tail is directly pasted behind ring E with no linker
in between.
The Fusions Show Strongly Varying
Production Levels
The nisin and anti-Gram-negative tail fusions were produced
by the nisin inducible production system previously described,
which consists of NZ9000(pIL3EryBTC, pNZ8048-nisin
derivative) (Rink et al., 2005; van Heel et al., 2013). The
production levels were monitored by TCA precipitations of the
supernatants analyzed by tricine SDS-PAGE (Figure 2A). The
production levels of the fusion peptides vary greatly, mainly
depending on the types of the tail, e.g., the variants containing
the tail from apidaecin 1b (GNT1, GNT16 and GNT16-3rings),
oncocin (GNT6 and GNT7) and drosocin (GNT8) showed good
production levels. The fusions containing other kinds of tails
showed low production levels. Additionally, the MALDI-TOF
analysis showed that some variants were partly degraded (data
not shown). Furthermore, with the same kind of tail, the design
rules also affect the production level, e.g., GNT16-3rings showed
generally higher expression levels than GNT1 and GNT16.
To reduce the amount of extracellular proteases and obtain
more intact peptides, the deletion strain PA1001 (1acmA1htrA)
(Bosma et al., 2006) was tested to express some of the fusions
(Figure 2B). In this system, wild type nisin showed almost the
same production level as in the NZ9000 system, but the amount
of contaminant proteins was much less. In this case, the GNT3SG
(containing Bac8c) was expressed in high amounts. The mutants
GNT16 and GNT16SG also showed good production and the
production level of GNT16SG was even higher.
The Nisin and Anti-Gram Negative Tail
Fusions were Characterized by MS
The fusions with relatively higher production levels (GNT1,
GNT6, GNT7, GNT8, GNT16, GNT16 -3 rings, and GNT16SG)
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TABLE 3 | Sequences of nisin and anti-Gram-negative tail fusions.
Peptides Sequence
Group 1 Architecture Ring ABC + hinge region + tail
GNT1 Ring ABC +NMKVYIPRPRPPHPR
GNT1+L Ring ABC +NMKVYIPRPRPPHPRL
GNT4 Ring ABC + NMKGNNRPVYIPRPRPPHPRL
GNT5 Ring ABC + NMKPRPPHPRLNMKPRPPHPRL
GNT16− 3 rings Ring ABC + NMKPRPPHPRL
GNT6 Ring ABC + NMKPPYLPRPRPPRRIYNR
GNT7 Ring ABC + NMKPRPRPPRRIYNR
GNT8 Ring ABC + NGKPRPYSPRPTSHPRPIRV
GNT2 Ring ABC + NMRLLFRKIRRLKR
GNT10− 3 rings Ring ABC + NMRIWVIWRR
GNT11− 3 rings Ring ABC + NMKLFKKILKYL
GNT12− 3 rings Ring ABC + NMRRLFRRILRWL
GNT15− 3 rings Ring ABC + NMGKHVGKALKGLKGLLK
Group 2 Architecture Nisin + tail
GNT16 Nisin + PRPPHPRL
GNT17 Nisin + PRPRPPRRIYNRN
GNT10 Ring ABCDE + SIHVSRIWVIWRR
GNT11 Nisin + LFKKILKYL
GNT12 Ring ABCDE + SIHVSRRLFRRILRWL
GNT15 Nisin + GKHVGKALKGLKGLLK
Nisin + 8 R Nisin + RRRRRRRR
Group 3 Architecture Nisin △VSK+ tail
GNT161VSK Nisin △VSK + PRPPHPRL
GNT161IHVS Nisin △IHVS + PRPPHPRL
GNT101VSK Nisin △VSK + RIWVIWRR
GNT121VSK Nisin △VSK + RRLFRRILRWL
GNT151VSK Nisin △VSK + GKHVGKALKGLKGLLK
Group 4 Architecture Ring ABCDE + SG + tail
GNT2SG Ring ABCDE + SG + RLLFRKIRRLKR
GNT3SG Ring ABCDE + SG + RIWVIWRR
GNT12SG Ring ABCDE + SG + RRLFRRILRWL
GNT15SG Ring ABCDE + SG + GKHVGKALKGLKGLLK
GNT16SG Ring ABCDE + SG + PRPPHPRL
GNT17SG Ring ABCDE + SG + PRPRPPRRIYNRN
GNT3 Ring ABCDE+RIWVIWRR
The additional anti-Gram-negative tail is underlined.
were further purified and characterized by MS after leader
peptide cleavage. After purification, the variants GNT1, GNT16,
GNT16 -3rings, and GNT16SG showed almost pure peaks, while
the GNT6, GNT7, and GNT8 contained degradation products
(Supplementary Figure 1). The mass of the degraded peptides
(Supplementary Table 1) indicates that the peptides GNT6,
GNT7, and GNT8 tend to be degraded at the C-terminus, with
the C-terminal R, NR, YNR, IYNR, or IRV deleted.
The dehydration extent of the intact peptides was analyzed,
and the results (Table 4) showed that the GNT1, GNT6, GNT7,
GNT16, GNT16 -3 rings, and GNT16SG were fully dehydrated.
The GNT8 fusion contains 2 serines and 1 threonine in the tail,
and the full peptide was dehydrated seven times, thus five times
in the nisin part and two in the tail.
Effect of EDTA on the Activity of Nisin
against E. coli
Nisin normally shows low activity against Gram-negative
organisms. In this research, we determined a MIC value
of nisin of 16µM against E. coli CECT101 (Table 5). As
described before, nisin can inhibit the growth of Gram-negative
bacteria when a sufficient amount of EDTA(>100µM) was
added (Helander and Mattila-Sandholm, 2000). In this research,
different concentrations of EDTAwere added together with nisin.
The results show that as the concentration of EDTA went up, less
nisin was needed to exhibit full inhibition.
The Fusions Displayed Lower Net Activity
than Nisin against L. lactis
Nisin inhibits the growth of L. lactis MG1363 at the nanomolar
range (6 nM Table 6). However, when equipped with a tail,
the MIC values against L. lactis increased and ranged between
200 nM (GNT16 and GNT7) and 1000 nM (GNT1 and GNT16-
3rings). The activity of GNT16SG against L. lactis was two times
lower than GNT16, but 2.5 times higher than GNT16-3rings.
Activity of the Fusions against
Gram-Negative Bacteria
Table 6 shows the activities of nisin and the fusions against E. coli
CECT101. The peptides GNT1, GNT6, GNT7, GNT8, GNT16
-3rings, and GNT16SG showed lower net activity than nisin
against E. coli, while GNT16 displayed two times higher activity
than nisin (Table 6). In addition, the mutants GNT6, GNT7,
and GNT8 were a mix of intact and partly degraded peptide
(Supplementary Figure 1). Figure 3 shows that 4µM GNT16
displayed better inhibitory activity than 8µMnisin, whichmeans
that the activity of GNT16 was more than two times higher
than that of nisin. GNT16 showed a significant improvement
comparable to the concentration of nisin needed in the presence
of 110µM EDTA. Furthermore, GNT16 also showed an equal or
slightly better inhibitory activity than nisin against E. coliCIP and
Enterobacter aerogenes CECT684, which exhibited lower growth
after prolonged incubation (Supplementary Figure 2).
DISCUSSION
The concomitant use of nisin with other compounds to increase
the inhibition effects against Gram-negatives has been described.
For instance, the combination with polymyxin E (Naghmouchi
et al., 2013) or with chelating agents such as EDTA (Boziaris
and Adams, 1999) gave a better inhibition. There are also genetic
engineering products which have improved activity.Mutating the
hinge region of nisin Z and thereby increasing the positive charge
was found to make nisin slightly more active against several
species of Gram-negative bacteria, such as Shigella, Pseudomonas
and Salmonella but not E. coli (Yuan et al., 2004). In the study of
Field et al. (2012), S29 of nisin was mutated into G, A, or E, which
resulted for all themutants in a two-fold increased activity against
E. coli 0157-H7 and Salmonella enterica serovar Typhimurium.
In our research, the outer membrane-passing capacity of nisin
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FIGURE 2 | Coomassie-blue stained tricine SDS-PAGE gel. The fusion peptides were produced with NZ9000 (A) or with PA1001 (B). Each well contains TCA
precipitated peptides from 600µl supernatant. All the samples are prepeptides with the leader and his tag part still attached. The experiment was performed several
times showing similar results.
TABLE 4 | Mass of nisin and nisin with anti-Gram-negative tail fusions.
Peptides Number of
dehydrations
Predicted mass
(Da)
Observed mass
(Da)
Nisin 8 3355.1 3353.5
GNT1 5 3607.5 3606.7
GNT6 5 4171.1 4169.3
GNT7 5 3700.6 3702.4
GNT8 7 4025.9 4026.5
GNT16 8 4306.3 4304.3
GNT16-3rings 5 3091.9 3092.8
GNT16SG 7 3816.7 3818.9
TABLE 5 | Minimum inhibition concentration (MIC) of nisin against E.coli
CECT101 in the presence of different concentration of EDTA.
Concentration of EDTA (µM) MIC value of nisin against E. coli
CECT101(µM)
0 16
25 16
110 8
250 4
was aided by attaching some highly positive charged (at least four
positive charges) antimicrobial peptides as a tail. These AMPs are
usually rich in proline, arginine, lysine, and hydrophobic amino
acids. In contrast to polymyxin E and EDTA, which disrupt the
stability of the outer membrane (Naghmouchi et al., 2013; Clifton
et al., 2015), the AMPs go into the cells without breaking the
outer membrane. They tend to form a helical structure when
interacting with the negatively charged outer membrane and
at the same time transit the membrane (Torcato et al., 2013).
With this kind of tail as a sort of Trojan horse, the trans-outer
membrane efficiency of nisin probably could be increased.
The peptide GNT16 contains a full length nisin and a tail from
apidaecin 1b. Apidaecin 1b is a kind of proline-rich AMP, which
TABLE 6 | Activities of nisin and nisin-tail fusions.
Peptides MIC valuea (µM)
E. coli CECT101 L. lactis MG1363
Nisin 16 0.006
GNT1 >16 1
GNT6* >16 ND
GNT7* >16 0.2
GNT8* >16 ND
GNT16 8 0.2
GNT16-3rings >32 1
GNT16SG >32 0.4
aThe experiments were repeated at least two times. *These peptides were mixed with
partial C-terminal degradation products. ND, not determined.
FIGURE 3 | Inhibitory effects of nisin and GNT16 against E. coli
CECT101. Either 16µM nisin or 8µM GNT16 could fully inhibit the growth of
bacteria within 18 h. The experiment was repeated three times.
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inhibits the growth of Gram-negative bacteria by translocation
into the cytoplasm and binding the chaperone DnaK. Api88
is a derivative of apidaecin 1b with increased positive charges
and an amidated C-terminus, which displays higher activity. The
crystal structure of DnaK and Api88 showed that residues 5–
11(PVYIPRP) of Api88 bind to DnaK. The tail (PRPPHPRL),
which does not display DnaK binding activity, probably has a
good outer membrane and inner membrane-passing capability
(Czihal et al., 2012). In this research, the nisin-PRPPHPRL
fusion showed increased activity compared to nisin against E.
coli, which is probably because the tail has improved the trans-
outer membrane capability of the peptide. Furthermore, the
fusion GNT16 showed 32 times decreased activity against L. lactis
MG1363, which means that attaching the tail is detrimental
for the original inhibition activity of nisin probably due to the
elimination of the pore forming ability of nisin (Rink et al.,
2007b).
Interestingly, the part of nisin that is retained in the fusion
affects the activity of the fusion peptide. The GNT16SG displayed
two times lower activity than GNT16 against L. lactis, and more
than four times lower activity against E. coli. The GNT16-3 rings
displayed even more reduced activity than GNT16SG against
both strains. This indicates that the intertwined rings and the last
six amino acids of nisin are helpful for the activity. Normally,
a helical conformation is formed during the AMPs passing the
outer membrane. The C-terminus of nisin has a helical structure
(van de Ven et al., 1991) as well, which may be helpful for the
outer membrane passing capacity. Alternatively, a longer linker
could be beneficial for the tail from apidaecin 1b to form a PP II
helix (polyproline helical type II) (Li et al., 2006), and traverse the
outer membrane.
The fusion GNT7 consists of the first three rings of nisin and a
PRPRPPRRIYNR tail from oncocin. The partly purified GNT7
displayed equal activity as GNT16 against L. lactis and higher
activity thanGNT16-3rings andGNT16SG, whichmeans that the
GNT7 possibly displays relatively better pore formation activity.
We have seen that all the peptides in this research are active
against L. lactis (data in Supplementary Figure 3). This is in
accordance with the literature, which indicates that the first three
rings of nisin retain activity (Rink et al., 2007b). However, as most
of the peptides were expressed at very low levels or were degraded
after expression, full length fusions are difficult to obtain. To
overcome this problem, some in vitro synthesis methods (e.g.,
solid-phase peptide synthesis) might be employed to increase the
success rate of this novel design (Montalbán-López et al., 2012).
Some kinds of AMPs (e.g., Api 88, oncocin, Bac8c, R-BP100,
RW-BP100, and ADP2) contain a C-terminal amide, which can
increase the activity. If the fusion peptides could be amidated
as well, probably the activities against Gram-negatives could be
enhanced. However, to the best of our knowledge there are no
in vivo amidation strategies available in L. lactis. The stability
of the tails is very important for the production level of the
fusions. The seven fusions obtained in this research contain tails
from apidaecin 1b, oncocin, and drosocin, which indicates that
proline-rich AMPs are more stable and easier to be expressed in
L. lactis. The production level of GNT16-3rings > GNT16SG >
GNT16>GNT161VSK>GNT161IHVS, which indicates that a
shorter part of nisin (first three or five rings) can render a higher
production level but also that the last five residues of nisin form
a weak region.
Compared to apidaecin 1b which can inhibit the Gram-
negative organisms at 0.5µM (Berthold et al., 2013), the best
fusion peptide showed still a 16-fold higher MIC value, although
the experimental setup is different. To increase the activity of
nisin against Gram-negative bacteria, both the inhibition activity
and trans-outer membrane activity are important. When the
first three rings of nisin are intact, the lipid II binding activity
is stable. Retaining the pore formation activity is crucial. By
further variation of the linker between the nisin part and the
tail or searching for more efficient tails, higher pore formation
activity and trans-outer membrane efficiency can undoubtedly
be obtained. Moreover, after the fusion peptides enter the
periplasm, particular periplasmic proteases might be used to
liberate both compounds. In this way, both nisin and the anti-
Gram-negative peptides could perform their inhibitory activity
more efficiently although this point need further study. The
periplasmic HtrA protease might be a good candidate to cleave
the fusions (Lipinska et al., 1990). Our data combining in a single
nisin derivative the lipid II binding activity of nisin with the
penetrating activity of eukaryotic antimicrobial peptides indicate
that a rational design can improve the activity of lantibiotics
against Gram-negative bacteria.
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